Cedazuridine hydrochloride

Cat. No.: HY-109081A

Molecular Formula: $C_9H_{15}ClF_2N_2O_5$

Molecular Weight: 304.68

Target: Others

Pathway: Others

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Cedazuridine (E7727) (Compound 7a) hydrochloride is an orally active cytidine deaminase (CDA) inhibitor with an IC_{50} value of 0.4 μM. Cedazuridine hydrochloride can be used for cancer research[1].
IC_{50} & Target	IC_{50}: 0.4 μM (CDA)[1]
In Vitro	Cedazuridine (Compound 7a) exhibits superior acid stability[1]. Cedazuridine (0-10 μM; 72 h) does not enhance effects of AZA (5-Azacytidine, HY-10586) in growth inhibition of AML cell lines [2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Cedazuridine (3 mg/kg; p.o.; daily for 7 days) in combination with 2.5 mg/kg AZA shows tumor regression in mice MOLM-13 CDX and PDX models[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female NSGS mice, 6–8 weeks old, human cell line-derived (CDX) and primary patient-derived xenograft (PDX) models[2]
Dosage:	3 mg/kg
Administration:	Oral administration, in combination with 2.5 mg/kg AZA, daily for 7 days
Result:	Led to reduction of leukemic expansion in combination with AZA in a cell line-derived xenograft transplantation, and exhibited preliminary safety and efcacy in a primary AML PDX model.

Animal Model:	NSGS male mice[2]
Dosage:	1, 3, 10 and 30 mg/kg
Administration:	Oral, in combination with 2.5 mg/kg AZA (Pharmacokinetic Studies)
Result:	Dose-dependently increased the AUC of oral AZA and in comparison to dosing of standard i.p. AZA.

REFERENCES

[1]. Ferraris D, et al. Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase. J Med Chem. 2014 Mar 27; 57(6):2582-8.

[2]. Ramsey H E, et al. Oral azacitidine and cedazuridine approximate parenteral azacitidine efficacy in murine model. Targeted Oncology, 2020, 15(2): 231-240.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA